+

WO2001096878A3 - Marqueur pour maladies neurodegeneratives et son utilisation pour le criblage de medicaments diriges contre lesdites maladies - Google Patents

Marqueur pour maladies neurodegeneratives et son utilisation pour le criblage de medicaments diriges contre lesdites maladies Download PDF

Info

Publication number
WO2001096878A3
WO2001096878A3 PCT/BE2001/000100 BE0100100W WO0196878A3 WO 2001096878 A3 WO2001096878 A3 WO 2001096878A3 BE 0100100 W BE0100100 W BE 0100100W WO 0196878 A3 WO0196878 A3 WO 0196878A3
Authority
WO
WIPO (PCT)
Prior art keywords
marker
drug screening
neurodegerative diseases
nucleotide sequence
active portion
Prior art date
Application number
PCT/BE2001/000100
Other languages
English (en)
Other versions
WO2001096878A2 (fr
Inventor
Roland Pochet
Bernhard Keller
Claus Heizmann
Original Assignee
Univ Zuerich
Univ Bruxelles
Roland Pochet
Bernhard Keller
Claus Heizmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich, Univ Bruxelles, Roland Pochet, Bernhard Keller, Claus Heizmann filed Critical Univ Zuerich
Priority to AU2001265714A priority Critical patent/AU2001265714A1/en
Publication of WO2001096878A2 publication Critical patent/WO2001096878A2/fr
Publication of WO2001096878A3 publication Critical patent/WO2001096878A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une trousse de diagnostic pour la détection et/ou la quantification d'une maladie ou d'une pathologie neurodégénérative. Cette trousse comprend une structure antigénique renfermant la protéine de liaison au calcium S100A6 (calcycline) ou une partie active (épitope) de ladite protéine, une molécule dirigée contre cette structure antigénique (ou contre une partie active de cette structure) et/ou une séquence nucléotidique capable de s'hybrider avec la séquence nucléotidique codant pour ladite protéine.
PCT/BE2001/000100 2000-06-14 2001-06-14 Marqueur pour maladies neurodegeneratives et son utilisation pour le criblage de medicaments diriges contre lesdites maladies WO2001096878A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001265714A AU2001265714A1 (en) 2000-06-14 2001-06-14 Marker for neurodegenerative diseases and its use for drug screening targeted against said diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21141200P 2000-06-14 2000-06-14
US60/211,412 2000-06-14

Publications (2)

Publication Number Publication Date
WO2001096878A2 WO2001096878A2 (fr) 2001-12-20
WO2001096878A3 true WO2001096878A3 (fr) 2002-06-13

Family

ID=22786822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BE2001/000100 WO2001096878A2 (fr) 2000-06-14 2001-06-14 Marqueur pour maladies neurodegeneratives et son utilisation pour le criblage de medicaments diriges contre lesdites maladies

Country Status (2)

Country Link
AU (1) AU2001265714A1 (fr)
WO (1) WO2001096878A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009109862A2 (fr) * 2008-03-06 2009-09-11 Rolf Lewensohn Substances thérapeutiques anticancéreuses améliorées
EP2418491A1 (fr) * 2010-08-10 2012-02-15 Bioftalmik, S.L. Procédé pour le diagnostic de la sécheresse oculaire et de la blépharite

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001471A1 (fr) * 1996-07-05 1998-01-15 Ab Sangtec Medical Methodes pour determiner la presence de la proteine cerebrale s-100
WO1998037420A1 (fr) * 1997-02-24 1998-08-27 Markus Otto Procede pour diagnostiquer l'encephalopathie spongiforme transmissible

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001471A1 (fr) * 1996-07-05 1998-01-15 Ab Sangtec Medical Methodes pour determiner la presence de la proteine cerebrale s-100
WO1998037420A1 (fr) * 1997-02-24 1998-08-27 Markus Otto Procede pour diagnostiquer l'encephalopathie spongiforme transmissible

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HEIZMANN CLAUS W ET AL: "New perspectives on S100 proteins: A multi-functional Ca2+-, Zn2+- and Cu2+-binding protein family.", BIOMETALS, vol. 11, no. 4, December 1998 (1998-12-01), pages 383 - 397, XP008001661, ISSN: 0966-0844 *
HEIZMANN CLAUS W: "Ca2+-binding S100 proteins in the central nervous system.", NEUROCHEMICAL RESEARCH, vol. 24, no. 9, 1999, pages 1097 - 1100, XP008001662, ISSN: 0364-3190 *
HOYAUX DAPHNE ET AL: "S100 proteins in Corpora amylacea from normal human brain.", BRAIN RESEARCH, vol. 867, no. 1-2, 2000, pages 280 - 288, XP002194140, ISSN: 0006-8993 *
PERSSON L ET AL: "S-100 PROTEIN AND NEURON-SPECIFIC ENOLASE IN CEREBROSPINAL FLUID AND SERUM MARKERS OF CELL DAMAGE IN HUMAN CENTRAL NERVOUS SYSTEM", STROKE, vol. 18, no. 5, 1987, pages 911 - 918, XP000913410, ISSN: 0039-2499 *
TONINI G P ET AL: "Gene expression and protein localisation of calcyclin, a calcium-binding protein of the S-100 family in fresh neuroblastomas.", EUROPEAN JOURNAL OF CANCER, vol. 31A, no. 4, 1995, pages 499 - 504, XP002194141, ISSN: 0959-8049 *

Also Published As

Publication number Publication date
AU2001265714A1 (en) 2001-12-24
WO2001096878A2 (fr) 2001-12-20

Similar Documents

Publication Publication Date Title
WO2005027733A3 (fr) Marqueurs biologiques destines au diagnostic de la sclerose en plaques
WO2002061135A3 (fr) Selection de sequences par jeu ordonne d'echantillons d'adn
AU2002330215A1 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
WO1999058639A3 (fr) Proteines de structure du virus de la maladie affectant le pancreas des poissons et utilisations de ces dernieres
WO2004099240A3 (fr) Peptides et certains de leurs melanges convenant a la detection du coronavirus associe au syndrome respiratoire aigu severe (sras)
WO2001096878A3 (fr) Marqueur pour maladies neurodegeneratives et son utilisation pour le criblage de medicaments diriges contre lesdites maladies
AU2002213450A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
WO2004083241A3 (fr) Proteines interagissant avec btc et utilisation de ces proteines
AU2002239256A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
WO2001077305A3 (fr) Variantes de la sous-unite gamma-3 humaine de la proteine kinase activee par l'amp
WO2002024738A1 (fr) Proteine localisee nucleaire de beta-catenine
AU2002239444A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002095413A3 (fr) Chlamydia hote contenant un phage, impliquee dans les maladies vasculaires
WO2001064875A3 (fr) Nouveaux transporteurs humains 20685, 579, 17114, 23821, 33894 et 32613
WO2002029023A8 (fr) Proteine appelee nicastrine
WO2002033058A3 (fr) Proteases a cysteine
AU2002234023A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
WO2006032021A3 (fr) Identification de gene associe a deficience de lecture et ses utilisation
WO2006089422A8 (fr) Proteine et son utilisation pour diagnostiquer la maladie d'alzheimer
WO2003052412A3 (fr) Liaison genetique
AU2001288688A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU2001292687A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU2002223183A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2004005332A3 (fr) Peptides secretes
WO2002070558A3 (fr) Domaine de liaison du ligand du recepteur hormonal nucleaire

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载